BridgeBio have significantly boosted its progress of the novel treatment for cardiac amyloidosis, leveraging the investigational drug. Preliminary clinical data suggests significant outcomes for those suffering with https://biotech001221.p2blogs.com/40446233/firm-advances-cardiac-amyloidosis-therapy-using-attruby